Vol 47, No 1 (2009)
Original paper
Submitted: 2011-12-19
Published online: 2009-05-08
Soluble angiogenesis markers in gastric tumor patients.
Piotr Mysliwiec, Krystyna Pawlak, Roman Bandurski, Bogusław Kedra
DOI: 10.2478/v10042-009-0004-4
·
Folia Histochem Cytobiol 2009;47(1):81-86.
Vol 47, No 1 (2009)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2009-05-08
Abstract
Gastric cancer is the second commonest cause of cancer-associated death in the world. Its molecular markers can be useful not only for diagnostic, but also prognostic purposes. The aim of the study was to assess the usefulness of soluble angiogenesis markers such as endoglin and VEGFR2 in gastric cancer patients and to compare these results with those of VEGF levels. As a secondary objective, we compared the concentrations of all three soluble markers in plasma and serum. The study was performed on 26 patients with gastric cancer (17 intestinal-type and 9 diffuse-type), and additionally in 2 patients with B cell lymphoma and 2 with gastro-intestinal stromal tumor. In summary, we showed increases in circulating VEGF-A in patients with both types of gastric cancer. The levels of VEGFR2 did not change significantly in patients with gastric cancer as compared to healthy subjects. Interestingly, after the operation greater levels of VEGFR2 were observed in patients without metastases. Both VEGF and VEGFR2 circulating levels were greater in patients with lymphoma, when compared to both gastric cancer patients and the control group. However, because of small number of patients, this requires further studies. Presented data suggests that endoglin does not seem to be a valuable tool in the assessment of gastric cancer invasion and spread.
Abstract
Gastric cancer is the second commonest cause of cancer-associated death in the world. Its molecular markers can be useful not only for diagnostic, but also prognostic purposes. The aim of the study was to assess the usefulness of soluble angiogenesis markers such as endoglin and VEGFR2 in gastric cancer patients and to compare these results with those of VEGF levels. As a secondary objective, we compared the concentrations of all three soluble markers in plasma and serum. The study was performed on 26 patients with gastric cancer (17 intestinal-type and 9 diffuse-type), and additionally in 2 patients with B cell lymphoma and 2 with gastro-intestinal stromal tumor. In summary, we showed increases in circulating VEGF-A in patients with both types of gastric cancer. The levels of VEGFR2 did not change significantly in patients with gastric cancer as compared to healthy subjects. Interestingly, after the operation greater levels of VEGFR2 were observed in patients without metastases. Both VEGF and VEGFR2 circulating levels were greater in patients with lymphoma, when compared to both gastric cancer patients and the control group. However, because of small number of patients, this requires further studies. Presented data suggests that endoglin does not seem to be a valuable tool in the assessment of gastric cancer invasion and spread.
Title
Soluble angiogenesis markers in gastric tumor patients.
Journal
Folia Histochemica et Cytobiologica
Issue
Vol 47, No 1 (2009)
Article type
Original paper
Pages
81-86
Published online
2009-05-08
Page views
2054
Article views/downloads
1958
DOI
10.2478/v10042-009-0004-4
Bibliographic record
Folia Histochem Cytobiol 2009;47(1):81-86.
Authors
Piotr Mysliwiec
Krystyna Pawlak
Roman Bandurski
Bogusław Kedra
About this article